Christian Kellner
Overview
Explore the profile of Christian Kellner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peipp M, Dudziak D, Kellner C
Signal Transduct Target Ther
. 2024 Jul;
9(1):172.
PMID: 38982080
No abstract available.
2.
Biedermann A, Patra-Kneuer M, Mougiakakos D, Buttner-Herold M, Mangelberger-Eberl D, Berges J, et al.
Haematologica
. 2024 Jun;
109(12):3928-3940.
PMID: 38934068
Macrophages are one of the key mediators of the therapeutic effects exerted by monoclonal antibodies, such as the anti-CD19 antibody tafasitamab, approved in combination with lenalidomide for the treatment of...
3.
Windisch R, Soliman S, Hoffmann A, Chen-Wichmann L, Danese A, Vosberg S, et al.
Proc Natl Acad Sci U S A
. 2024 Jun;
121(25):e2312499121.
PMID: 38857395
Ex vivo expansion of human CD34+ hematopoietic stem and progenitor cells remains a challenge due to rapid differentiation after detachment from the bone marrow niche. In this study, we assessed...
4.
Xhaxho S, Chen-Wichmann L, Kreissig S, Windisch R, Gottschlich A, Nandi S, et al.
Transfus Med Hemother
. 2024 Apr;
51(2):111-118.
PMID: 38584695
Introduction: Primary human blood cells represent an essential model system to study physiology and disease. However, human blood is a limited resource. During healthy donor plateletpheresis, the leukoreduction system chamber...
5.
Schewe D, Vogiatzi F, Munnich I, Zeller T, Windisch R, Wichmann C, et al.
Hemasphere
. 2024 Mar;
8(2):e48.
PMID: 38435424
CD19-directed immunotherapy has become a cornerstone in the therapy of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). CD19-directed cellular and antibody-based therapeutics have entered therapy of primary and relapsed disease and...
6.
Lutz S, Klausz K, Albici A, Ebinger L, Sellmer L, Teipel H, et al.
Front Immunol
. 2023 Nov;
14:1227572.
PMID: 37965326
The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of...
7.
Zeller T, Munnich I, Windisch R, Hilger P, Schewe D, Humpe A, et al.
Front Immunol
. 2023 Oct;
14:1240275.
PMID: 37781391
Immune checkpoint blockade is a compelling approach in tumor immunotherapy. Blocking inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer and may hold potential to...
8.
Gottschlich A, Thomas M, Grunmeier R, Lesch S, Rohrbacher L, Igl V, et al.
Nat Biotechnol
. 2023 Mar;
41(11):1618-1632.
PMID: 36914885
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid...
9.
Zeller T, Lutz S, Munnich I, Windisch R, Hilger P, Herold T, et al.
Front Immunol
. 2022 Nov;
13:929339.
PMID: 36389667
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by 'Don´t Eat Me!' signals such as CD47 expressed by cancer cells. Yet, human...
10.
Gehlert C, Rahmati P, Boje A, Winterberg D, Krohn S, Theocharis T, et al.
Front Immunol
. 2022 Sep;
13:957874.
PMID: 36119088
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent...